Yan'an University Affiliated Hospital Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
2017
NCT02982668
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Yan'an University Affiliated Hospital | Yan'an University Xianyang hospital Co., Ltd

Active Ingredients

Drugs in Phase 4 Trials (2)

anlotinib (1 trial)

tenofovir alafenamide (genvoya) (1 trial)

Drugs in Phase 3 Trials (1)

borneol (1 trial)

Drugs in Other Trials (3)

bivalirudin (angiomax) (1 trial)

erythromycin (ilosone) (1 trial)

heparin (liquaemin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 6